Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH

Annamaria Iorio; V. Blanchette; J Blatny; P. Collins; K Fischer; E Neufeld

doi:10.1111/jth.13867

Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH

Annamaria Iorio, V. Blanchette, J Blatny, P. Collins, K Fischer, E Neufeld

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	2461-2465
Number of pages	5
Journal	Journal of Thrombosis and Haemostasis
Volume	15
Issue number	12
DOIs	https://doi.org/10.1111/jth.13867
Publication status	Published - Dec 2017

Access to Document

10.1111/jth.13867

Cite this

@article{e5381114c19444a2b0f13e6b5ebcd98b,

title = "Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH",

author = "Annamaria Iorio and V. Blanchette and J Blatny and P. Collins and K Fischer and E Neufeld",

note = "Funding Information: V. Blanchette has received honoraria for participating in educational events and advisory boards funded by Bayer, Biogen, Novartis, Novo Nordisk, Pfizer, and Shire. He is a member of Data Safety Monitoring Boards for Octa-pharma and Shire. He is Chair of the International Prophylaxis Study Group, a collaborative study group that receives funding support from Bayer, Biogen, CSL Behring, Novo Nordisk, Pfizer, and Shire. J. Blatny has received speaker{\textquoteright}s fees from Bayer, Baxter, CSL Behring, Octa-pharma, Pfizer, and Novo Nordisk, and performed consultancy for Shire, Baxter, Novo Nordisk, and Pfizer. P. Collins has received research support from CSL Behring, consultancy fees from Novo Nordisk, Sobi, Shire, and CSL Behring, and sponsorship for meetings from Novo Nordisk, CSL Behring, and Shire. K. Fischer has received speaker{\textquoteright}s fees from Bayer, Baxter, Biotest, CSL Behring, Biotest Octapharma, Pfizer, and Novo Nordisk, performed consultancy for Bayer, Baxter, Biogen, Freeline, Novo Nordisk, and Pfizer, and received research support from Bayer, Wyeth/Pfizer, Baxter, and Novo Nordisk. A. Iorio{\textquoteright}s Institution has received project-based funding via research or service agreements with Bayer, Baxalta/Shire, Biogen Idec, Grifols, Novo Nordisk, Pfizer, and Octapharma. E. Neufeld has served as a consultant for Novo Nordisk, Genentech, Pfizer, CSL Behring, Kedrion, Genentech, and Octapharma. He is also a DSMB member for Bayer. His institution has received research funds from Octapharma. All authors are co-investigators in the Web Accessible Population Pharmacokinetic Service (WAPPS) research project.",

year = "2017",

month = dec,

doi = "10.1111/jth.13867",

language = "English",

volume = "15",

pages = "2461--2465",

journal = "Journal of Thrombosis and Haemostasis",

issn = "1538-7933",

publisher = "Wiley-Blackwell",

number = "12",

}

Iorio, A, Blanchette, V, Blatny, J, Collins, P, Fischer, K & Neufeld, E 2017, 'Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH', Journal of Thrombosis and Haemostasis, vol. 15, no. 12, pp. 2461-2465. https://doi.org/10.1111/jth.13867

Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. / Iorio, Annamaria; Blanchette, V.; Blatny, J et al.
In: Journal of Thrombosis and Haemostasis, Vol. 15, No. 12, 12.2017, p. 2461-2465.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach

T2 - communication from the SSC of the ISTH

AU - Iorio, Annamaria

AU - Blanchette, V.

AU - Blatny, J

AU - Collins, P.

AU - Fischer, K

AU - Neufeld, E

N1 - Funding Information: V. Blanchette has received honoraria for participating in educational events and advisory boards funded by Bayer, Biogen, Novartis, Novo Nordisk, Pfizer, and Shire. He is a member of Data Safety Monitoring Boards for Octa-pharma and Shire. He is Chair of the International Prophylaxis Study Group, a collaborative study group that receives funding support from Bayer, Biogen, CSL Behring, Novo Nordisk, Pfizer, and Shire. J. Blatny has received speaker’s fees from Bayer, Baxter, CSL Behring, Octa-pharma, Pfizer, and Novo Nordisk, and performed consultancy for Shire, Baxter, Novo Nordisk, and Pfizer. P. Collins has received research support from CSL Behring, consultancy fees from Novo Nordisk, Sobi, Shire, and CSL Behring, and sponsorship for meetings from Novo Nordisk, CSL Behring, and Shire. K. Fischer has received speaker’s fees from Bayer, Baxter, Biotest, CSL Behring, Biotest Octapharma, Pfizer, and Novo Nordisk, performed consultancy for Bayer, Baxter, Biogen, Freeline, Novo Nordisk, and Pfizer, and received research support from Bayer, Wyeth/Pfizer, Baxter, and Novo Nordisk. A. Iorio’s Institution has received project-based funding via research or service agreements with Bayer, Baxalta/Shire, Biogen Idec, Grifols, Novo Nordisk, Pfizer, and Octapharma. E. Neufeld has served as a consultant for Novo Nordisk, Genentech, Pfizer, CSL Behring, Kedrion, Genentech, and Octapharma. He is also a DSMB member for Bayer. His institution has received research funds from Octapharma. All authors are co-investigators in the Web Accessible Population Pharmacokinetic Service (WAPPS) research project.

PY - 2017/12

Y1 - 2017/12

U2 - 10.1111/jth.13867

DO - 10.1111/jth.13867

M3 - Article

C2 - 29119666

SN - 1538-7933

VL - 15

SP - 2461

EP - 2465

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

IS - 12

ER -